Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00371670 · ClinicalTrials.gov registry record · Phase 2

Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee

A Phase 2 study of Knee Osteoarthritis, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
223
Enrollment target
2
Study locations

NCT00371670 is a Phase 2 study of Knee Osteoarthritis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 223 participants, below the 302-participant average among 101 other Knee Osteoarthritis trials with a reported enrollment target (26% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00371670, a Phase 2 study of Knee Osteoarthritis, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
223 participants
Enrollment target
2
Study locations

Study Summary

This study will test efficacy and safety of AAE581 compared to placebo in limiting cartilage loss in patients with painful knee osteoarthritis which is confirmed by X-ray

Conditions Studied

Interventions

  • DRUG balicatib (AAE581)

Study Locations (2)

Alabama

  • Pinnacle Research Group - Anniston

Other

  • Novartis - Nuremberg

Trial Details

FieldValue
Enrollment Target 223 participants
Start Date 2004-12
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

What the Registry Record Tells You About NCT00371670

The ClinicalTrials.gov registry entry for NCT00371670 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 101 other Knee Osteoarthritis trials with a reported enrollment target (26% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Knee Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which balicatib (AAE581) is the first listed.

NCT00371670 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Alabama, Other.

Frequently Asked Questions

What is clinical trial NCT00371670 about?

NCT00371670 is a clinical study titled "Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee". This study will test efficacy and safety of AAE581 compared to placebo in limiting cartilage loss in patients with painful knee osteoarthritis which is confirmed by X-ray

What is the current status of trial NCT00371670?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 223 participants. The study started on 2004-12.

What conditions does trial NCT00371670 study?

This clinical trial studies the following conditions: Knee Osteoarthritis.

What interventions are being tested in trial NCT00371670?

The interventions under investigation include: balicatib (AAE581) (DRUG).

Who is sponsoring clinical trial NCT00371670?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00371670 being conducted?

This trial has 2 study locations across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Knee Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.